Advancing RNA

ARW ON RNA

The Cell-Free Revolution: Breaking The Plasmid DNA Bottleneck

I was excited to be given the opportunity to sit down with Jodi Barrientos, CEO, Ribbon Bio, to learn more about the current state of the synthetic DNA space. In the following Q&A, Barrientos and I discuss some of the synthetic DNA industry’s biggest goals and the challenges that stand in the way of bringing synthetic plasmids more commonly into the mRNA development paradigm.

OUR EXPERT NETWORK

RNA Modification-Mediated Translational Control In Immune Cells
Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.
Repeating Sanofi's Ballroom Design On Two Continents
Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance
A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease
Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset
In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

WEBINARS

Enhancing Gene Editing Outcomes And Safety for Clinical Translation With Next Generation Vectors

Unlocking The Next Wave Of Cancer Vaccines

Optimizing Antibody Variant Capture: Strategies To Combat Aggregation, Impurities, And Low Yields

Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

Your AKTA Oligosynt™ System : It's More Than A Machine

Take The Wheel And Drive Your Oligo Synthesis Where You Want

Five Practical Considerations To Move From Concept To Clinic

Hear From The Experts: LNPs Driving The Future Of Cell Therapy

MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.

Start the conversation by following me on LinkedIn!

RNA HOT TAKES

VIRTUAL EVENTS

More Virtual Events

NEWSLETTER ARCHIVE

More Newsletters